
Review article**Invasive candidiasis; a review article****Majid Zarrin¹, Ali Zarei Mahmoudabadi^{1,2}**¹Department of Medical Mycology, School of Medicine, and ²Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran**Received:** March 2009**Accepted:** March 2009

Abstract

The epidemiology of *Candida* fungal infections is growing, due to the increasing size of the people at risk. *Candida* species are the fourth main cause of bloodstream infections; however, significant geographic differences have been reported. Although, in some instances, these changes may be related to medical interventions, such as the use of antifungal agents in prophylaxis, in the majority of cases, they seem to be a consequence of changes in the host, such as more-severe immunosuppression or different types of immunosuppression impacting both risk periods and the infections that occur. Discussion of surveillances and reports will be critical to improve our understanding of the importance of invasive *Candida* infections, and to facilitate the prioritization of the investigation as well as the prevention efforts.

Keywords: Candidiasis, Invasive candidiasis, *Candida albicans***Introduction**

The epidemiology of invasive fungal infection has changed during the last two decades. The frequency of the disease has increased, and the population of patients at risk has expanded to include those with an extensive list of medical conditions, such as solid organ and hematopoietic stem cell transplantation (HSCT), receipt of immunosuppressive therapy, human immunodeficiency virus (HIV) infection, premature birth, advanced age, surgery and cancer [1]. Moreover, the etiology of invasive mycoses has also changed. In the 1980s, yeasts (mainly *Candida albicans*) were the most frequent causative agents of invasive fungal infections. Despite of its benefits, medical development has led to a susceptible population with suppressed immunological defenses against fungal infection. These factors heighten the risk for

many invasive fungal infections, including candidiasis, aspergillosis, cryptococcosis, and mucormycosis [2].

Epidemic of HIV is a major factor that has contributed to a remarkable increase in the frequency of invasive candidiasis. Before the extensive use of highly active anti-retroviral therapy (HAART) in developed countries, 80% of HIV-infected patients developed mucosal candidiasis, while others developed cryptococcosis, pneumocystosis and other lethal mycoses, for example, penicilliosis [2,3]. Candidiasis, a main cause of death in patients with leukemia and solid organ transplants or recipients of stem cell, is currently observed more frequently among patients in intensive care units (ICUs). The species of *Candida* causing infection are more diverse. *C. albicans* is the most frequent pathogen followed by *C. glabrata*, *C. tropicalis* and *C. parapsilosis*.

***Candida* invasive infections**

Bloodstream infection by *Candida* species (candidemia) is the most frequent clinical manifestation of invasive candidiasis, and is a significant cause of morbidity and mortality in hospitalized patients. *Candida* species are the fourth most widespread cause of hospital-acquired bloodstream infections in the United States [4-5], with a frequency of 1.5 cases per 10,000 patients days [6]. In a comparable European survey, the frequency is slightly lower, at 0.5-0.7 cases per 10,000 patients days [7-10]. Currently, the highest reported incidence of healthcare related candidemia (3.7 cases per 10,000 patients days) comes from an eleven-center sentinel observation plan in Brazil [11]. While the reasons for this high rate of infection are not obvious, several factors could be involved, including the availability of less resources for medical care and training programs, difficulties in the achievement of infection control programs in hospitals of developing countries, limited numbers of health-care staffs, and less effective practices of antifungal drug treatment in high-risk patients.

Candidemia is usually connected with infection outside of bloodstream. In numerous patients the yeast spreads from the gastrointestinal tract to other organs and this helps to elucidate why *Candida* bloodstream infection is similar to a devastating disease. In the United States, the mortality rate for candidemia in medical centers from 1997 to 2001 was 49% [12], which was 11% higher than that detected in the same hospital from 1983 to 1986 [13]. Analysis of the epidemiological researches that evaluates the varying incidence of *Candida* bloodstream infection over time is complicated. However, it is necessary to find important dissimilarities in the results coming from various countries or various centers.

In the Netherlands, the incidence rate of candidemia among hospitalized patients rose from 0.37 to 0.72 cases per 10,000 patient days between 1987 and 1995 [14]. But in Switzerland, the rate remains approximately

permanent between 1991 and 2000 (median incidence: 0.5 cases per 10,000 patient days) [3]. In Iran 45% of kidney recipients and 84% of liver recipients had *Candida* colonization in different sites of their bodies [15]. A research in Iran showed that disseminated candidiasis was the second common cause of invasive fungal infections [16]. In the past years, the main groups at risk for serious *Candida* diseases were cases that were neutropenic, had received transplants, or had been treated with cytotoxic or corticosteroids drugs. At present, the patients who are in the ICU, are the most susceptible to show severe *Candida* infections. The most high risk patients are those who have a central venous catheter, are receiving parenteral nutrition or are on broad-spectrum antibiotics and have high Acute Physiology and Chronic Health Evaluation scores [17-19]. The fourth most frequent cause of nosocomial bloodstream infection among ICU patients is *Candida* species. Moreover, these yeasts are the third most widespread cause of nosocomial bloodstream infections [5]. The mortality of candidemia remains about 40% [12].

Etiologic agents

There are now approximately 200 species of *Candida*, but only a few have been involved in human infection. Ninety percent of all *Candida* bloodstream infection globally have been caused by five species: *C. albicans*, *C. glabrata*, *C. parapsilosis*, *C. tropicalis*, and *C. Krusei* [6,9,11,20]. The remaining diseases have been caused by several other *Candida*, including *C. dubliniensis*, *C. famata*, *C. guilliermondii*, *C. lusitaniae*, *C. norvegensis*, *C. pelliculosa*, and *C. rugosa* [9,11,20,21]. Though these species are unusual causes of candidiasis, some of them are recognized to happen in nosocomial clusters, or display innate, or even obtained resistance to antifungal drugs [22,23].

Candida albicans remains the predominant cause of candidemia worldwide. The frequency of invasive

candidiasis which is recovered from blood samples varies according to geographical setting, and demographics of the population studied. Broad use of fluconazole for treatment of HIV-infected cases with persistent oropharyngeal candidiasis resulted in the selection of *Candida* species essentially less sensitive to azoles in the early 1990s. The azole-drug resistant strains in these patients emerged because of acquisition of resistance with previously sensitive strains of *C. albicans* [24]. This occurrence has led to the concern that extensive fluconazole use in broader patient populations could cause related selections for species and strains that possess inherent or acquired azole resistance. Nevertheless, the frequency of fluconazole resistance among *C. albicans* bloodstream isolate, gathered in population-based and sentinel surveillance programs worldwide, stays insignificant [6,9,11].

A new trend noted in numerous hospitals is an enhancement in the frequency of *C. glabrata* as serious *Candida* infections [25,26]. There are some reasons for this increase, including the living habitat, age and type of the patients, and use of fluconazole. *C. glabrata* is usually noted in persons older than 60 years [26] and in patients who have leukemia or received a stem cell transplant, and those who are associated with increasing use of fluconazole [27]. The significance of this epidemiologic trend is that *C. glabrata* is frequently resistant to fluconazole, the drug used most often for the treatment of candidemia. Though candidemia is the main type of invasive candidiasis, broad visceral invasion with *Candida* can happen by persistently negative blood cultures. Almost all organs can be infected, although the kidneys, eyes, liver, spleen, and brain are most frequently involved. Signs of invasive infection that ought to be clinically diagnosed are endophthalmitis or chorioretinitis as well as the emergence of painless skin lesions.

Treatment

The patients with confirmed candidemia or invasive candidiasis must be treated with an antifungal drug [28]. The elevated rate of spreading to main organs, once *Candida* obtains entrance to the bloodstream, offers the basis for this approach. There are primarily two goals in the treatment of candidiasis, interference with *Candida* proliferation in the body and the reduction of the factors providing favorable environment for growth of *Candida*.

Several antifungal drugs are available for the treatment of candidiasis. These consist of fluconazole, voriconazole, caspofungin, amphotricin B, and lipid formulations of amphotricin B. Studies confirm that fluconazole, caspofungin, and voriconazole are as valuable as amphotricin B deoxycholate in the treatment of candidemia [29]. Fluconazole is the preferred treatment of candidemia. Fluconazole is effective against most species of *Candida*. The drug has been revealed to be as useful as amphotricin B in nonneutropenic patients. Nevertheless, fluconazole has restricted activity against *C. glabrata* and is not effective against *C. krusei*. Combination therapy may be used to cope with treatment failures [30-34]. Doctors should become aware of the most frequent species of *Candida* causing bloodstream invasive infection at their centers. Vascular catheter removal enhances the clearance of *Candida* from the blood [35]. Daily blood culture is required to confirm that the problem of fungemia is resolved, and treatment must continue for two weeks following the date of the primary negative blood culture.

Laboratory diagnosis

The disease is very difficult to diagnose because some of the etiologic agents of disease are also commonly observed in healthy people. As a result, laboratories have an important role in detection of diseases and identification of etiologic agents of them. In addition, they can help with the

selection and the monitoring of antifungal therapy. Information that is essential for laboratory workers is as follows; the clinical history of patients, occupation, the source of the samples, any prior treatment with antifungal, anti-microbial and immuno-suppressive drugs, the method by which the samples were collected and types of transport medium.

The patients must not take any antifungal drugs three days before sampling. For urinary sampling, 10 ml of midstream or catheter specimens should be collected in a sterile test tube. Cerebrospinal fluid (CSF) samples provide good specimens for patients with candidal meningitis. CSF are usually, collected by a clinician using a routine lumbar puncture technique. In candidemia 20 ml of blood from adults or 1-5 ml from children is collected and directly inoculated into the blood culture medium (Biphasic medium). Suitable specimens for respiratory candidiasis are early morning sputum and bronchial washing collected in a sterile screw-cap container. The samples should be digested by KOH or N-acetyl cysteine or pancreatin before preparing smears and cultures. Another method for sampling from candidiasis is biopsy from organs.

Direct examination of specimens and observation of fungal elements in clinical materials is a very important part of laboratory diagnosis. As a result, a correct report can help the clinician prescribe suitable treatment. Furthermore, in acute diseases, such as *Candida* meningitis and systemic candidiasis in AIDS patients, rapid direct microscopy can play a very important role in suitable treatment. For liquid specimens, such as urine, saliva, sputum, and CSF, firstly, centrifuge and then microscope slides can be prepared from their sediments. The microscope slides should be stained by Gram, Giemsa or methylene blue stains. Tissue sections should be stained using Periodic Acid Schiff, Grocott's methenamine silver or Gram stain. Ovoid yeast cells, budding cells (3-7 μ m in diameter), true hyphae, pseudohyphae or

both are the morphological forms of *Candida* species that are usually seen in clinical materials. Positive direct microscopy from a biopsy or a sterile site, such as blood, CSF and vitreous and joint fluid, are significant, whether of yeast or pseudohyphae. According to Talwar *et al.* [36] the presence of mycelial forms of *Candida* in direct microscopy is as a diagnostic marker for candidiasis; however, when *C. glabrata* is the etiologic agent of disease, pseudohyphae is not observed in smears.

All clinical materials are cultured on the suitable culture medium. There are a number of culture media for isolation of *Candida* species from clinical materials but the selective medium most often used is Sabouraud's dextrose agar (SDA) with chloramphenicol or other anti-bacterial agents. Many species of *Candida* (*C. krusei*, *C. parapsilosis* and *C. tropicalis*) are sensitive to cycloheximide, which is why media with cycloheximide should not be for isolation of *Candida* species. SDA is recommended for isolation and culture of *Candida* species. CHROMagar *Candida* is a new medium that is used for isolation and identification of some clinically important *Candida* species. The incubation temperature for cultures is 30-37°C for 24-72 h (37,38).

Conclusion

Invasive candidiasis is recognized as a cause of infection with increased incidence in the past two decades. This expected increase reflects several factors, such as changes in hosts at risk and progress in diagnostic methods. The appearance of *Candida* with variable susceptibilities to antifungal agents emphasizes the clinical importance of establishing fungal diagnoses. Changes in hosts sensitive to *Candida* infection, diagnostic approaches, practice patterns, and probable changes in climatic influences, will possibly continue to amend the epidemiology for years to come.

References

- 1) Morse SS, Factors and determinations of disease emergence. *Revue Scientifique et Technique* 2004; 2: 443-446.
- 2) Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. *Drugs* 2008; 68: 1941-1962.
- 3) Fidel PL jr. *Candida* host interactions in HIV disease: relationships in oropharyngeal candidiasis. *Advances in Dental Research* 2006; 1: 80-84.
- 4) Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream in United States hospitals: a three-year analysis. *Clinical Infectious Disease* 1999; 29: 239-244.
- 5) Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clinical Infectious Disease* 2004; 39: 309-317.
- 6) Hajjeh RA, Safair AN, Harrison LH, *et al.* Incidence of bloodstream infections due to *Candida* species and *in vitro* susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. *Journal of Clinical Microbiology* 2004; 42: 1519-1527.
- 7) Richet H, Roux P, Des Champs C, Esnault Y, Andreumont A. Candidemia in French hospitals: incidence rates and characteristics. *Clinical Microbiology Infection* 2002; 8: 405-412.
- 8) Marchetti O, Bille J, Flukiger U, *et al.* Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. *Clinical Infectious Disease* 2004; 38: 311-320.
- 9) Alimirante B, Rodriguez D, Park BJ, *et al.* Epidemiology and predictors of mortality in cases of *Candida* bloodstream infection: results from population based surveillance, Barcelona, Spain from 2002 to 2003. *Journal of Clinical Microbiology* 2005; 43: 1829-1835.
- 10) Arendrup MC, Fursted K, Gahrn-Hansen B *et al.* Semi national surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. *Journal of Clinical Microbiology* 2005; 43: 4434-4440.
- 11) Colombo AL, Nucci M, Park BJ, *et al.* Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centres. *Journal of Clinical Microbiology* 2006; 44: 2816-2823.
- 12) Gudlaugsson O, Gillespie S, Lee K, *et al.* Attributable mortality of nosocomial candidemia, revised. *Clinical Infectious Disease* 2003; 37: 1172-1177.
- 13) Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. *Archives of Internal Medicine* 1988; 148: 2642-2645.
- 14) Voss A, Kluytmans JA, Koelman JG, *et al.* Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. *European Journal of Clinical Microbiology Infectious Disease* 1996; 15: 909-912.
- 15) Badiie P, Kordbacheh P, Alborzi A, *et al.* Fungal infections in solid organ recipients. *Experimental and Clinical Transplantation* 2005; 3: 385-389.
- 16) Einollahi B, Lessan-Pezeshki M, Pourfarziani V, *et al.* Invasive fungal infections following renal transplantation: A review of 2410 recipients. *Annual Transplantation* 2008; 13: 55-58.
- 17) Pappas PG, Rex JH, Lee J, *et al.* A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clinical Infectious Disease* 2003; 37: 634-643.
- 18) Rangel-Frausto MS, Wiblin T, Blumberg HM, *et al.* National epidemiology of mycoses survey (NEMIS): variations in rate of bloodstream infections due to *Candida* species in seven surgical intensive care units and six neonatal intensive care units. *Clinical Infectious Disease* 1999; 29: 253-258.
- 19) Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related deaths in cardiothoracic ICU patients. *Chest* 2003; 124: 2244-2255.
- 20) Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of

- Candida* species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. *Journal of Antimicrobial Chemotherapy* 2004; 53: 283-289.
- 21) Sandven P, Bevanger L, Digraabes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. *Journal of Clinical Microbiology* 2006; 44: 1977-1981.
 - 22) Colombo AL, Melo AS, Crespo Rosas RF, et al. Outbreak of *Candida rugosa* candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. *Diagnostic and Microbiology Infectious Disease* 2003; 46: 253-257.
 - 23) Masala L, Luzzati R, Maccacaro L, Antozzi L, Concia E, Fontana R. Nosocomial cluster of *Candida guilliermondii* fungemia in surgical patients. *European Journal of Clinical Microbiology Infectious Disease* 2003; 22: 686-688.
 - 24) Sanglard D, Odds FC. Resistance of *Candida* species to antifungal agents: molecular mechanisms and clinical consequences. *Lancet Infectious Disease* 2002; 2: 73-85.
 - 25) Baddley JW, Smith AM, Moser SA, Pappas PG. Trends in frequency and susceptibilities of *Candida glabrata* bloodstream isolates at a university hospital. *Diagnostic Microbiology Infectious Disease* 2001; 39: 199-201.
 - 26) Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in species causing fungemia in a tertiary care medical centre over 12 years. *Mycoses* 2001; 44: 446-449.
 - 27) Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. *Journal of Infectious Disease* 2000; 181: 309-316.
 - 28) Pappas JH, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. *Clinical Infectious Disease* 2004; 38: 161-189.
 - 29) Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *New England Journal of Medicine* 2002; 347: 2020-2029.
 - 30) Zarrin M, Afsharpoor R. The study of antifungal effects of miconazole and nystatin separately and in combination with each other against *Candida albicans*. *Ahvaz Scientific Medical Journal* 1998; 23: 20-25.
 - 31) Zarei Mahmoudabadi A, Farrahei F, Zarrin M. *In vitro* synergism between miconazole and griseofulvin against *Candida* species. *Pakistan Journal of Medical Sciences* 2006; 22: 454-456.
 - 32) Barchiesi F, Giacometti A, Cirioni O. *In vitro* activity of the synthetic protegsetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of *Candida* Spp. *Journal of Chemotherapy* 2007; 19: 514-518.
 - 33) Huang S, Cao YY, Dai BD, et al. *In vitro* synergism of fluconazole and baicalein against clinical isolates of *Candida albicans* resistant to fluconazole. *Biological and Pharmaceutical Bulletin* 2008; 31: 2234-2236.
 - 34) Zarrin M, Jamshidian M, Jafari M. *In vitro* interactions of miconazole with sulfametoxazole against *Candida* species. *Pakistan Journal of Medical Sciences* 2009; (In press).
 - 35) Rex JH, Bennett JE, Sugar AM. Intravascular catheter exchanges and the duration of candidemia. *Clinical Infectious Disease* 1995; 21: 994-996.
 - 36) Talwar P, Chakrabarti A, Chawla A, et al. Fungal diarrhea: association of different fungi and seasonal variation in their incidence. *Mycopathologia* 1990; 110: 101-105.
 - 37) Zarei Mahmoudabadi A, Keradmand AR, Enayatollahi N. Frequency of Candiduria in hospitalized inpatients and out patients in the department of urology Golestan hospital, Ahvaz, Iran. *Iranian Journal of Kidney Diseases* 2009; 2: 114-115.
 - 38) Zarei Mahmoudabadi A, Drucker DB, Mandall N, Brien KO, Theaker E. Isolation and identification of *Candida* species from the oral cavity using CHROMagar Candida. *Iranian Biomedical Journal* 2000; 4: 57-61.

Address for correspondence:

Majid Zarrin, Department of Medical Mycopathology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
 Tel: +98611 3330074; Fax: +98611 3332036
 Email: mjzarrin@yahoo.co.uk